Seattle Genetics, Inc. (NASDAQ: SGEN) today highlighted final five-year survival results from a phase 1 clinical trial evaluating ADCETRIS (brentuximab ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Hot FDA News Management Comments

Seattle Genetics (SGEN) and Takeda Highlight Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS (brentuximab vedotin) in Frontline Advanced Hodgkin LymphomaDecember 11, 2017 5:45 AM Seattle Genetics (SGEN) Presents Updated Analyses from Phase 3 ALCANZA Clinical Trial of ADCETRIS (Brentuximab Vedotin) in CD30-Expressing Cutaneous T-Cell LymphomaDecember 11, 2017 5:39 AM Seattle Genetics Highlights Five-Year Survival Results from Phase 1 Trial of ADCETRIS® (Brentuximab Vedotin) in Frontline Mature T-Cell Lymphoma at ASH Annual MeetingDecember 10, 2017 9:00 AM Seattle Genetics (SGEN) Announces Updated Phase 1 Data for Ladiratuzumab Vedotin (SGN-LIV1A)December 7, 2017 8:01 AM